ACRS Aclaris Therapeutics, Inc.
8-K Current Report
Filed: March 11, 2026
Health Care
Pharmaceutical PreparationsAclaris Therapeutics, Inc. (ACRS) 8-K current report filed with SEC EDGAR on March 11, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 7.01 · Regulation FD Disclosure
- • Reg FD disclosure filed March 11, 2026, signed by CFO Kevin Balthaser — no substantive operational or financial data included in the text
- • Full disclosure content contained in referenced exhibit — investors should review attached exhibit for material information
Other Aclaris Therapeutics, Inc. 8-K Filings
Get deeper insights on Aclaris Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.